RESUMO
Bladder papillomatosis offers a good target to evaluate IFN-alpha systemic treatment. We carried out a pilot study on eight multiple bladder papilloma patients under the same treatment scheme (1 x 10(6) IU/amp. every 48 h over six months), and they were followed-up for over two years after treatment. Recurrent patients underwent a similar second treatment. IFN-alpha therapy showed the following variations of effects: total disappearance, size decrease or persistence of papillomas, neither size increase nor appearance of new ones, remarkable valuable recurrence frequency rate decrease in all cases, and recurrences with smaller papillomas. This IFN-alpha treatment scheme would be fit to carry out broader controlled studies to show frequencies of the different kinds of responses. The inclusion of a minimum (dose-frequency-period) IFN-alpha treatment period after the first six months' therapy is proposed in order to achieve total disappearance of recurrences.
Assuntos
Carcinoma de Células de Transição/tratamento farmacológico , Interferon Tipo I/uso terapêutico , Neoplasias Primárias Múltiplas/tratamento farmacológico , Neoplasias da Bexiga Urinária/tratamento farmacológico , Idoso , Avaliação de Medicamentos , Feminino , Humanos , Interferon Tipo I/administração & dosagem , Masculino , Pessoa de Meia-Idade , Recidiva Local de Neoplasia/tratamento farmacológico , Fatores de TempoRESUMO
We have studied the vesical function in 4 prediabetics, 11 latent diabetics, 11 recent onset insulin dependent diabetics and a control group of 6 normal individuals. We found in recent onset of diabetics disturbances of cystometric parameters in a statistically significant proportion. This proportion increases with the evolution of diabetes. The difference in sensitivity to cold water that we found betwee SDB and NBD was statistically significant, so the denomination 'hyposensitive bladder' is well applied in this fist phase of vesical neuropathy.
